EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections

FibroBiologics Inc. (NASDAQ:FBLG) on Wednesday filed a U.S. patent application for a cell-based platform designed to produce therapeutic peptides continuously inside the human body, offering a potential long-term alternative to traditional weight-loss and diabetes treatments. Cellular Innovation For Peptide Secretion Popular GLP-1 medications currently require patients to receive regular weekly injections or take daily pills. FibroBiologics engineered living cells—grouped into small three-dimensional structures known as spheroids or organoids—to function as miniaturized internal peptide factories. Once clinicians administer these cellular aggregates, the cells continually release therapeutic peptides directly into the patient. Read Also: FibroBiologics Says Preclinical Data Shapes Design of Further Studies for Degenerative Joint Treatment Expanding Platform Beyond Single Indications The patent application explicitly covers GLP-1, GIP, and GLP-2 class peptides while establishing a broad therapeutic platform. Beyond metabolic disorders like diabetes and obesity, the technology targets gastrointestinal diseases, autoimmune and inflammatory conditions, wound healing, tissue regeneration, hormone deficiencies, cancer, and age-related conditions. The technology utilizes various cell types, including engineered fibroblasts, stem cells, and immune cells. It supports single-secretion models alongside unimolecular dual or triple agonists and antagonists. Distinct cell populations within the aggregates can secrete separate peptides simultaneously, enabling customized hormone balances tailored to specific diseases or individual patient profiles. Overcoming Supply Bottlenecks And Prioritizing Safety Global demand for GLP-1 and incretin treatments continues to experience constraints from patient compliance issues, injection burdens, dose spikes, and manufacturing bottlenecks. Continuous cellular secretion aims to overcome these hurdles by providing stable, physiological levels following a single administration. Features include immune-evasive modifications for off-the-shelf allogeneic application, inducible safety switches that enable cell elimination on demand, genomic safe-harbor integration, and encapsulation inside biocompatible scaffolds or retrievable devices that give physicians complete governance over dosage and therapy duration. FBLG Price Action: FibroBiologics shares were down 1.28% at $1.11 during premarket trading on Wednesday, according to Benzinga Pro data. Read Also: Jim Cramer Recommends This ‘Really Well-Run’ Energy Stock Image via Shutterstock